Check for updates

OPEN ACCESS

EDITED BY Remo Furtado, Brazilian Clinical Research Institute, Brazil

REVIEWED BY

Antonio Aurelio De Paiva Fagundes Junior, D'Or Institute for Research and Education (IDOR), Brazil Flavia Bittar Britto Arantes,

Universidade Federal de Uberlândia, Brazil *CORRESPONDENCE

Jiankai Zhong ⊠ doctor-zh@smu.edu.cn

RECEIVED 01 June 2023 ACCEPTED 04 September 2023 PUBLISHED 13 September 2023

CITATION

Chen S, Guan S, Yan Z, Ouyang F, Li S, Liu L and Zhong J (2023) The lactate to albumin ratio linked to all-cause mortality in critically ill patients with septic myocardial injury. Front. Cardiovasc. Med. 10:1233147. doi: 10.3389/fcvm.2023.1233147

COPYRIGHT

© 2023 Chen, Guan, Yan, Ouyang, Li, Liu and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The lactate to albumin ratio linked to all-cause mortality in critically ill patients with septic myocardial injury

Sheng Chen¹, Senhong Guan¹, Zhaohan Yan¹, Fengshan Ouyang², Shuhuan Li³, Lanyuan Liu⁴ and Jiankai Zhong^{1*}

¹Department of Cardiology, Shunde Hospital, Southern Medical University, Foshan, China, ²Department of Rehabilitation Medicine, Shunde Hospital, Southern Medical University, Foshan, China, ³Department of Pediatrics, Shunde Hospital, Southern Medical University, Foshan, China, ⁴Department of Ultrasound Medicine, Shunde Hospital, Southern Medical University, Foshan, China

Background: The lactate to albumin ratio (LAR) has emerged as a promising prognostic marker in critically ill patients. Despite its potential utility, the prognostic value of LAR in septic myocardial injury (SMI) remains uncertain.

Methods: This study aims to investigate the prognostic significance of LAR in SMI through a retrospective cohort analysis of data from the Medical Information Mart for Intensive Care III (MIMIC-III) (v1.4) database. The study included intensive care unit (ICU)-admitted patients (age \geq 18 years) diagnosed with SMI. The primary endpoint was in-hospital mortality.

Results: A total of 704 patients were included in the study, of which 59.10% were male. Hospital mortality and ICU mortality rates were recorded at 29.97% and 22.87%, respectively. After adjusting for confounding factors, multivariate Cox proportional risk analysis demonstrated that LAR was independently associated with an increased risk of both hospital mortality (HR, 1.39 [95% CI: 1.24–1.56] P < 0.001) and ICU mortality (HR, 1.46 [95% CI: 1.29–1.65] P < 0.001). Furthermore, the generalized additive model (GAM) and restricted cubic spline (RCS) model indicated a linear relationship between LAR and mortality rates in the ICU and hospital.

Conclusions: The LAR may serve as a potential prognostic biomarker in critically ill patients with SMI. High LAR levels are associated with a higher risk of in-hospital mortality and can help identify individuals with high mortality rates. Overall, the findings emphasize the importance of using LAR as a tool for risk stratification and management of critically ill patients with SMI.

KEYWORDS

lactate/albumin ratio, septic myocardial injury, cox proportional hazards regression, intensive care unit, all-cause mortality

1. Introduction

Sepsis, a life-threatening condition caused by an overwhelming immune response to severe infection, is a significant contributor to global mortality. It has been estimated that approximately 30 million individuals are affected by sepsis annually, and the associated mortality rate is alarmingly high with 6 million deaths annually (1, 2). Multi-organ dysfunction is a common complication of sepsis and myocardial injury is frequently observed in sepsis patients, leading to myocardial dysfunction in more than 50% of patients (3, 4). Sepsis with myocardial injury is defined as SMI, which can lead to

complications such as severe arrhythmias, heart failure and cardiogenic shock (5). The early management of SMI plays a crucial role in improving patient prognosis. Therefore, it is imperative to establish a hierarchical management approach for SMI, which involves intervening based on risk stratification. Patients with a low-risk stratification should be closely observed, while those with a high-risk stratification require active intervention to effectively enhance patient prognosis and possibly reduce SMI mortality rates. Given these factors, there is an urgent requirement in clinical practice to identify easily obtainable and sensitive indicators for predicting the prognosis of SMI.

Elevated levels of blood lactate, which are indicative of tissue and organ dysfunction and low tissue perfusion, can result from anaerobic metabolism (6, 7). Meanwhile, albumin is a negative acute phase protein whose levels exhibit a negative correlation with the degree of inflammation (8-10). Prior studies have identified a relationship between sepsis status and prognosis and arterial blood lactate or serum albumin concentration (10-14). However, measures of lactate and albumin may be subject to some limitations as they can be influenced by other factors (15-17). Studies have suggested that the combination of these two measures in the form of LAR may provide more accurate predictive ability for sepsis compared to lactate alone (18, 19). Moreover, recent research has found that LAR is a reliable predictor of mortality in patients with heart failure and myocardial infarction (20, 21). Although one study (Zhang et al., n = 72) has evaluated the diagnostic value of LAR in severe pneumonia and myocardial injury, its prognostic value remains unexplored (22). Accordingly, this retrospective study aims to investigate the association between LAR and prognosis in patients suffering from SMI. Specifically, we analyze the value of LAR in assessing the status and predicting the prognosis of SMI.

2. Participants and methods

2.1. Data source

This was a retrospective observational study. The data for this analysis were obtained from the MIMIC-III database (v1.4). MIMIC-III is a large, open-access database containing information on patients admitted to ICU at a large tertiary hospital in Boston from 2001 to 2012 (23). In order to access this database, the first author of this study, Sheng Chen, completed the Collaborative Institutional Training Initiative (CITI) course and passed both the "Conflicts of Interest" and "Data or Specimens Only Research" exams (ID: 12046100). The database was approved for research use by Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center review boards, and informed consent was waived.

2.2. Population selection criteria

According to the definition of sepsis 3.0 (2), adult patients (\geq 18 years) with sepsis who had been hospitalized in the ICU at

first admission were included. Patients with the following criteria were excluded: (1) patients with cardiac troponin T (cTNT) ≤ 0.01 ng/ml at admission were excluded; (2) no lactate or albumin data during the ICU stay; (3) more than 20% variables missing. Finally, a total of 704 patients were included in the study cohort, and were divided into four groups according to the LAR quartile of the first day of hospitalization in ICU (**Figure 1**).

2.3. Variables

We use the Structured Query Language (SQL) with PostgreSQL (version 15.2) to extract data. The baseline characteristics included age, gender and weight. The comorbidities were defined with ICD-9 codes, including coronary artery disease (CAD), heart failure, hypertension, diabetes, hyperlipidemia, chronic kidney disease (CKD) and stroke. The following laboratory variables within the first day after ICU admission have also been extracted, including white blood cell (WBC), neutrophil percentage, lymphocyte percentage, platelet, hemoglobin, hematocrit, potassium, sodium, albumin, lactate, serum creatinine (Scr), blood urea nitrogen (BUN), cTNT, creatine kinase MB isoenzyme (CK-MB), alanine aminotransferase (ALT), aspartate aminotransferase (AST). The LAR was defined as the ratio of the lactate level to the albumin level. It was calculated as lactate (mmol/L)/[albumin (g/dl) × 10]. Furthermore, we also extracted the relevant severity scores for sepsis, including Sequential Organ Failure Assessment (SOFA) score, Systemic inflammatory response syndrome (SIRS) score, quick Sequential Organ Failure Assessment (qSOFA) score, Acute physiology score III (APS III), Simplified acute physiological score II (SAPS II). Finally, we also extracted the clinical treatment, including vasopressin use, ventilator use, and renal replacement therapy (RRT). The participants were followed from the date of admission to the date of death, or until hospital discharge.

To avoid bias, variables with more than 20% missing are excluded, such as C-reactive protein, lactate dehydrogenase, and height. A single imputation method was used to impute missing values for variables with up to 5% missing. For variables with missing values greater than 5% and less than 20%, we use the multiple imputation method and select the relatively optimal data set to impute the missing values (Supplementary Table S1).

2.4. Endpoint events and clinical definition

The primary study endpoint was in-hospital all-cause mortality, including hospital mortality and ICU mortality. According to the definition of sepsis3.0, the diagnostic criteria for sepsis is infection + SOFA score ≥ 2 points. We defined sepsis patients with cTnT levels above the upper limit of normal reference values (cTnT >0.01 ng/ml) as SMI, and excluded acute coronary syndrome (ACS).



2.5. Statistical analysis

Student's *t*-test or Kruskal–Wallis *H*-test were used to compare continuous variables, which are presented as mean ± standard deviation or median with interquartile range. Categorical variables are presented as frequencies and percentages, and differences between groups were compared using Pearson chi-square test or Fisher's exact test. We used Kaplan-Meier survival analysis to assess the incidence of primary outcome events between groups according to different levels of LAR, and differences between groups were assessed using log-rank tests. The hazard ratio (HR) and 95% confidence interval (CI) between LAR and primary endpoints were estimated using Cox proportional hazard models and adjusted for multiple models. We also calculated the variance inflation factor to avoid

overfitting the model due to multicollinearity between variables. Variables with a variance inflation factor \geq 5 were excluded. Based on the inclusion of LAR groups according to quartiles, four multivariate models were constructed. Model 1: unadjusted; Model 2: adjusted for age, gender, and weight; Model 3: adjusted for age, gender, weight, CAD, heart failure, atrial fibrillation, hypertension, diabetes, hyperlipidaemia, CKD, stroke, vasopressin use, ventilator use, and RRT; Model 4: adjusted for age, gender, weight, CAD, heart failure, atrial fibrillation, hypertension, diabetes, hyperlipidaemia, CKD, stroke, vasopressin use, ventilator use, RRT, WBC, neutrophil percentage, lymphocyte percentage, platelets, neutrophil/lymphocyte ratio (NLR), platelet/ neutrophil ratio (PNR), platelet/lymphocyte ratio (PLR), hemoglobin, potassium, sodium, Scr, BUN, CK-MB, ALT, AST, and SIRS score. We used RCS model and GAM to examine the

associations between LAR and outcomes. Based on the above results, we selected the lowest quartile of LAR values as the reference group. To determine the consistency of the prognostic value of LAR for the primary outcomes, we further stratified the analyses by age (<65 and ≥65 years), gender, CAD, heart failure, atrial fibrillation, hypertension, diabetes, hyperlipidemia, CKD, stroke, vasopressin use, ventilator use, and RRT. Likelihood ratio tests were used to examine interactions between the LAR and the variables used for stratification. The predictive ability of the LAR, lactate and albumin for in-hospital mortality was assessed using receiver operating characteristic (ROC) curves. Integrated discrimination improvement (IDI) and net reclassification improvement (NRI) are used to estimate the improvement in predictive ability after adding LAR to the scoring system. All statistical analyses were conducted with SPSS 27.0 software (IBM SPSS Statistics, Armonk, NY, USA) and R software version 4.2.2 (Institute for Statistics and Mathematics, Vienna, Austria). Statistical significance was defined as a two-tailed P-value <0.05.

3. Results

After reviewing the data of 38,511 patients who were admitted into the ICU from the MIMIC-III database, a total of 704 patients were included in this study. There were 288 (40.90%) females and 416 (59.10%) males. The median age of the enrolled patients was 68.94 years. The median LAR for all patients was 0.07. The hospital- and ICU-related mortality rates were 29.97% and 22.87%, respectively (Table 1).

3.1. Baseline characteristics

Table 1 shows the baseline characteristics of the study patients according to LAR quartiles. Patients were categorized according to the LAR values on admission (quartile [Q] 1: 0.02–0.05; Q2: 0.05–0.07; Q3: 0.07–0.12; Q4: 0.12–1.13). The median values of LAR of the four groups were 0.03, 0.06, 0.09 and 0.19, respectively. Patients with higher LAR had higher admission sickness scores, higher rates of vasopressin use, ventilation and RRT, higher WBC, lactate, albumin, CK-MB, ALT, AST and lower platelets, PNR, PLR compared with the lower group. **Table 2** shows the outcome events of the participants according to LAR quartiles. With increasing LAR value, ICU mortality (13.41% vs. 17.92% vs. 22.16% vs. 38.07%, P < 0.001) and hospital mortality (19.55% vs. 25.43% vs. 31.25% vs. 43.75%, P < 0.001) gradually increased.

The baseline characteristics of the survivor and non-survivor groups are summarized in **Supplementary Table S2**. Patients in the non-survivor group were older and had a lower prevalence of CAD, heart failure and CKD (P < 0.05). Regarding of laboratory parameters, participants with an endpoint event had higher levels of potassium, lactate, BUN, CK-MB, ALT, and AST, but lower levels of lymphocyte percentage, platelets, PNR, and albumin (P < 0.05). No significant differences were observed in gender, weight, hypertension, diabetes, hyperlipidemia, stroke, WBC, neutrophil percentage, NLR, PLR, hemoglobin, hematocrit,

sodium, Scr, and cTNT (P > 0.05). SOFA scores, SIRS scores, APS III and SAPS II were higher in the non-survivor group than in the survivor group. In the non-survivor group, the level of LAR was significantly higher than that of the survivor group (0.09 vs. 0.07, P < 0.001).

3.2. LAR level and in-hospital mortality

We plotted Kaplan-Meier survival analysis curves to observe the incidence of the primary endpoint event between groups according to LAR quartiles, as shown in **Figure 2**. In the hospital, a statistically significant difference in mortality was observed between the groups (log-rank P = 0.0017, **Figure 2A**). Significance was also observed in the ICU (log-rank P = 0.0014, **Figure 2B**).

Using GAM, we found that the relationship between LAR level and in-hospital mortality, including hospital mortality and ICU mortality, was linear (Figure 3). Similar results were seen in the RCS model (P for non-linearity = 0.343 and P for non-linearity = 0.418, respectively) (Figure 4). We used Cox proportional risk analysis, with the first quartile of the LAR as the reference group, to determine the association between the LAR and in-hospital mortality. The results demonstrated that it was associated with hospital mortality in both model 1 (Q1 vs. Q2: HR, 1.17 [95% CI: 0.75-1.83] P=0.487; Q3: HR, 1.53 [95% CI: 1.00-2.34] P=0.049; Q4: HR, 2.00 [95% CI: 1.34-3.00] P<0.001; P for trend = 0.002) and model 4 (Q1 vs. Q2: HR, 1.01 [95% CI: 0.64-1.61] *P* = 0.967; Q3: HR, 1.33 [95% CI: 0.85-2.08] *P* = 0.210; Q4: HR, 1.79 [95% CI: 1.16–2.77] *P* = 0.009; *P* for trend = 0.020), and showed a tendency to increase with the LAR (Table 3; Figure 5A). Further, Cox proportional risk analysis of the LAR and ICU mortality showed similar results (Table 3; Figure 5B).

3.3. Subgroup analysis

We performed subgroup analysis to assess the association between the LAR and hospital mortality, including age, gender, CAD, heart failure, atrial fibrillation, hypertension, diabetes, hyperlipidemia, CKD, stroke, vasopressin use, ventilator use, and RRT (Figure 6). In the subgroups of age <65 years [HR (95% CI) 1.43 (1.27–1.62)], those age ≥ 65 years [HR (95% CI) 1.29 (1.11-1.51)], those with female [HR (95% CI) 1.27 (1.07-1.52)], those with male [HR (95% CI) 1.35 (1.21-1.52)], those without CAD [HR (95% CI) 1.34 (1.21-1.49)], those without heart failure [HR (95% CI) 1.37 (1.23–1.52)], those without atrial fibrillation [HR (95% CI) 1.40 (1.25-1.56)], those without hypertension [HR (95% CI) 1.27 (1.11-1.47)], those with hypertension [HR (95% CI) 1.42 (1.24-1.61)], those without diabetes [HR (95% CI) 1.36 (1.22-1.51)], those without hyperlipidemia [HR (95% CI) 1.31 (1.18-1.46)], those with hyperlipidemia [HR (95% CI) 1.49 (1.18-1.88)], those without CKD [HR (95% CI) 1.38 (1.24-1.53)], those without stroke [HR (95% CI) 1.36 (1.23-1.49)], those without vasopressin use [HR (95% CI) 1.40 (1.18-1.66)], those with vasopressin use [HR (95% CI) 1.28 (1.13-1.45)], those without ventilator use [HR (95% CI) 1.58 (1.26-1.98)], those

Age, yam694, (52,78, 90.5)09.72 (09.77), 89.3)09.21 (09.08, 09.0)77. (43.75)04.41 (20.55, 79.32)0.009Frander286 (40.90)64 (37.90)100 (07.30)99 (56.57)70 (97.77)Male30.00 (70.06, 667)80.00 (60.80, 94.30)000 (68.15, 94.30)77 (43.75)18.18 (62.01)0.012Comorbidities, new50.00 (60.80, 94.30)64 (15.80, 18.76)55 (12.25)18.60 (62.03)0.001CAD22 (37.21)67 (37.44)70 (04.64)64 (37.50)57 (32.38)0.001Atrail Infuition262 (37.21)74 (41.34)70 (04.64)64 (37.50)77 (43.75)56 (13.20)0.002Diabeta266 (37.80)72 (40.22)61 (35.20)77 (43.75)56 (13.20)0.002Upperfusionin196 (27.84)57 (12.93)46 (12.59)49 (17.84)45 (15.75)0.039Stoke218 (09.09)67 (37.49)13.50 (18.70)13.95 (9.38, 19.09)11.95 (7.33, 18.65)0.044Upperfusionin98 (57.86)9.00 (70.98, 009)450 (75.57)84.20 (75.57, 80.90)83.00 (83.88, 82.7)0.034Ippatopte, %8.30 (51.00, 18.00)9.10 (15.00, 13.00)19.20 (146.00, 25.00)13.95 (9.38, 19.90)11.95 (7.33, 18.65)0.004Ipatopte, %8.30 (51.00, 18.00)9.10 (51.01, 13.40)9.10 (15.00, 14.00)13.95 (9.38, 19.40)11.95 (7.33, 18.50)0.304Ippatopte, %8.30 (51.00, 13.00)9.10 (51.00, 14.00)19.20 (14.00, 03.00)13.95 (9.38, 19.90)11.95 (7.33, 18.50)0.304 </th <th>Characteristics</th> <th>Overall (<i>n</i> = 704)</th> <th>Q1 (<i>n</i> = 179)</th> <th>Q2 (<i>n</i> = 173)</th> <th>Q3 (<i>n</i> = 176)</th> <th>Q4 (<i>n</i> = 176)</th> <th>P-value</th>	Characteristics	Overall (<i>n</i> = 704)	Q1 (<i>n</i> = 179)	Q2 (<i>n</i> = 173)	Q3 (<i>n</i> = 176)	Q4 (<i>n</i> = 176)	P-value			
Gender, n(s)mome </td <td>Age, years</td> <td>68.94 (57.78, 80.55)</td> <td>69.87 (59.77, 79.83)</td> <td>69.21 (60.86, 80.07)</td> <td>73.05 (59.60, 81.94)</td> <td>64.41 (52.05, 79.32)</td> <td>0.021</td>	Age, years	68.94 (57.78, 80.55)	69.87 (59.77, 79.83)	69.21 (60.86, 80.07)	73.05 (59.60, 81.94)	64.41 (52.05, 79.32)	0.021			
Famale288 (a)90)68 (3.90)77 (4.37)70 (0.37)70 (0.37)Walya10 (0.70)100 (70.00)100 (70.00)100 (70.00)100 (70.00)100 (70.00)Weight, Kg800 (0.70, 0.60)800 (0.80, 94.00)800 (0.82, 98.00)75 (35.10)8.18 (0.24, 01.000)100 (70.00)CDDDDELLES57 (37.41)67 (37.40)62 (35.40)57 (43.70)57 (37.30)0.000Harri fahrillation306 (45.50)67 (37.40)67 (37.40)77 (43.70)56 (13.20)0.000Phyperhalomica266 (37.60)72 (40.20)40 (20.50)40 (20.50)60 (37.00)10.000Kyperhalomica196 (37.60)15 (37.20)40 (20.50)40 (20.50)10.00010.000Kyperhalomica196 (37.60)15 (37.80)11.00 (37.10)12.05 (37.80)10.00010.000Kyperhalomica196 (37.00)15 (37.00)11.00 (37.10)12.05 (37.80)10.000 (37.80)10.000Kyperhalomica196 (37.00)11.00 (37.10)13.05 (37.80)10.000 (37.80)10.00010.000Kyperhalomica197 (37.80)10.000 (37.00)10.000 (37.00)10.000 (37.00)10.000 (37.00)10.000 (37.00)10.000 (37.00)Kyperhalomica198 (37.00)19.000 (37.00)13.000 (37.00)13.000 (37.00)10.000 (37.00)10.000 (37.00)10.000 (37.00)10.000 (37.00)Kyperhalomica19.00 (37.00)19.000 (37.00)19.000 (37.00)19.000 (37.00)10.000 (37.00)10.000 (37.00)10.000 (37.00)10.000 (37	Gender, <i>n</i> (%)						0.698			
MaleH11 (co)1010 (co)99 (co)102 (co)100 (co)Weigh, Ka800 (co)800 (co)800 (co)800 (co)80.00 (co)80.000 (co)<	Female	288 (40.90)	68 (37.99)	73 (42.20)	77 (43.75)	70 (39.77)				
<table-container>Weight spin spin spin spin spin spin spin spin</table-container>	Male	416 (59.10)	111 (62.01)	100 (57.80)	99 (56.25)	106 (60.23)				
Condition of 96CAD26.310)67.07.4362.05.84)58.02.95)36.02.05)0.002Heart failure306.04.530)89.09.72)88.08.00)77.(4375)57.02.38)0.004Atral failurio222.07.22)74.14.13170.60.64)66.07.50057.02.080.004Dabees226.07.80)77.04.2010.70.03.080.004Dabees226.07.80)77.04.2010.60.020.004Dabees226.07.80)75.02.0261.05.26)77.44.20575.02.080.004Stroke218.00.9067.07.41357.02.20552.02.55042.02.880.004Stroke57.08.0915.68.3818.10.4014.7.05510.10.5.880.004Horndrop parametry79.07.08.01.70.0011.60.04.01.57013.50.08.51.78.0013.50.7.68.31.90013.00.06.83.58.2500.004Parametry8.30.07.03.03.0991.00.01.53.0372.04.51.10.0010.000.00111.95.01.56.31.33.000.001Parametry8.30.07.03.03.0919.00.01.50.03.23021.50.01.40.03.01016.75.01.63.03.300.001Parametry8.30.07.03.0319.00.01.50.01.23012.00.14.50.01.20016.75.01.02.00.26.520.001Parametry8.30.07.03.0319.00.01.50.01.23012.00.14.50.21.0016.75.01.02.00.26.520.001Parametry8.30.07.03.0319.00.01.50.01.23012.00.14.50.21.0016.75.01.02.00.26.520.001Parametry8.30.07.03.0319.00.01.50.01.12.0011.00.07.03116.00.01.20.01 <td>Weight, Kg</td> <td>80.00 (67.00, 96.67)</td> <td>80.00 (68.00, 94.50)</td> <td>80.00 (68.25, 98.30)</td> <td>78.50 (65.73, 93.17)</td> <td>81.80 (62.40, 100.00)</td> <td>0.612</td>	Weight, Kg	80.00 (67.00, 96.67)	80.00 (68.00, 94.50)	80.00 (68.25, 98.30)	78.50 (65.73, 93.17)	81.80 (62.40, 100.00)	0.612			
CAD223 (31,70)0 7 (743)62 (35.84)88 (800)78 (32.5)10000Hart infultion260 (35.2)77 (41.4)70 (40.46)66 (37.50)77 (42.53)0.001Hart infultion26 (37.2)77 (41.4)70 (40.46)66 (37.50)72 (42.53)0.001Hypertension306 (45.50)72 (42.20)61 (35.50)77 (43.75)55 (31.82)0.010Hypertension196 (27.84)56 (31.28)44 (26.59)44 (27.84)45 (25.77)0.045Stock218 (30.96)67 (7.43)57 (32.95)22 (2.53)42 (2.86)0.041Stock12.70 (86.01,760)11.60 (84.01,57.0)13.50 (85.71,78)13.55 (98.71,90)11.95 (7.33, 18.05)0.041Laberatory parametric38.30 (75.06,870)83.90 (77.06,870)83.90 (77.06,870)83.90 (75.06,870)83.80 (65.31,83.20)0.040Lymphopic, %83.03 (51.0,13.00)9.01 (5.01,73.00)12.00 (14.00,73.00)11.85 (9.8.71,80)83.80 (68.31,83.20)0.040Lymphopic, %83.03 (50.0,870)83.90 (75.00,870)83.90 (75.9	Comorbidities, n (%)									
Heart failure306 (43.50)89 (49.27)83 (48.00)77 (42.76)(57.23)(0.04)Atrial fabrillation262 (37.22)74 (41.34)70 (40.64)66 (137.90)52 (29.55)40.03Diabets266 (37.80)72 (40.22)61 (35.26)77 (42.76)55 (13.20)0.040Diabets266 (37.80)75 (40.22)40 (25.80)47 (25.75)42 (23.80)0.010CKD218 (30.96)67 (37.43)57 (32.95)52 (29.55)42 (23.80)0.010Babets77 (80.97)11.60 (8.40, 15.70)13.50 (8.91, 17.60)13.95 (9.81, 19.00)11.95 (7.31, 18.05)0.014Pather12.70 (8.60, 17.60)11.60 (8.40, 15.70)13.95 (9.81, 19.00)11.95 (7.31, 18.05)0.014Stroke3.93 (57.00, 8.90)9.10 (30.1, 34.00)7.90 (43.0, 13.00)1.915 (6.1, 33.01)0.014Struker, Val3.930 (70.00, 8.900)192.00 (146.00, 25.80)12.50 (14.00, 20.83)8.20 (82.81, 18.83)0.014Struker, Val3.930 (70.00, 8.900)192.00 (14.00, 25.80)10.930 (14.00, 27.93)10.50 (10.20, 26.52)0.004Struker, Val3.930 (70.00, 8.900)192.00 (14.00, 27.80)10.85 (14.81, 78.40)10.50 (12.00, 26.20)0.004Struker, Val3.930 (70.00, 8.900)192.00 (14.00, 27.90)10.55 (12.00, 27.90)10.50 (13.00, 27.90)10.50 (13.0010.90 (13.0010.90 (13.0010.90 (13.0010.90 (13.0010.90 (13.0010.90 (13.0010.90 (13.0010.90 (13.0010.90 (13.0010.90 (13.0010.90 (13.0010.	CAD	223 (31.70)	67 (37.43)	62 (35.84)	58 (32.95)	36 (20.45)	0.002			
Anial Inditation326 (27.20)74 (41.24)97 (40.46)96 (74.24)97 (42.2	Heart failure	306 (43.50)	89 (49.72)	83 (48.00)	77 (43.75)	57 (32.38)	0.004			
Hyperingional Dabetes908 (43.0)77 (42.4)79 (45.6)77 (43.7)97 (43.7)90.01Dabetes266 (37.0)61 (32.0)41 (62.6)41 (74.8)45 (31.8)0.01CKD131 (80.00)75 (32.8)75 (32.8)75 (32.8)14 (73.8)42 (33.6)0.01Stroke75 (80.9)15 (83.8)131 (04.0)14 (75.9)110 (53.8)0.01Labote120 (80.1,70)11.04 (81.7)135 (85.7)84.70 (75.8)119 (73.1,80)9.01 (61.1,80)Stroke23.00 (14.0.2, 20.1)13.00 (80.2, 20.1)9.15 (61.1,80)9.15 (61.1,80)9.15 (61.1,80)9.15 (61.1,80)Stroke23.00 (14.0.2, 20.1)23.01 (15.0, 20.1,20)12.00 (14.0,12,80)12.00 (14.0,12,80)9.15 (11.0,12,12)12.00 (14.0,12,12)12	Atrial fibrillation	262 (37.22)	74 (41.34)	70 (40.46)	66 (37.50)	52 (29.55)	0.089			
Diabets266 (37.80)72 (40.22)61 (35.26)77 (4.37)55 (31.82)0.101Hynerhijdenia196 (27.84)56 (31.84)46 (36.59)49 (27.84)45 (25.57)42 (23.65)42 (35.67)Strok57 (8.09)15 (8.38)18 (10.40)14 (7.95)42 (35.68)0.043Babets57 (8.09)15 (8.38)18 (10.40)14 (7.95)10 (56.88)0.015 (36.98)NBC, Kul220 (80,61,760)11.60 (8.04,1570)13.59 (8.95,1500)13.95 (8.93,190)16.95 (3.63,13.04)0.001Naturophi, %83.95 (75.08, 88)9.01 (51.01,13.40)70 (53.01,530)7.20 (44.01,101)16.55 (10.02,05.26)0.001Patelack, Kul23.03 (10.01,22, 27.40)23.00 (16.05,01.01)19.03 (11.40,03,010)15.05 (10.02,05.26)0.001NRA0.94 (59.8, 166)9.01 (69.01,70.0)10.01 (14.00,03.00)10.01 (20.9,73.00)16.02 (10.01,73.40)0.001Patelack, Kul9.94 (59.8, 166)9.01 (69.01,70.0)10.01 (14.00,03.00)10.01 (20.9,73.00)16.02 (10.01,73.40)0.001NRA0.94 (59.8, 166)9.01 (69.01,70.0)10.01 (14.00,03.00)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (10.01,03.0)10.01 (1	Hypertension	306 (43.50)	76 (42.46)	79 (45.66)	74 (42.05)	77 (43.75)	0.904			
Hyperplemination196 (27.8)496 (28.8)49 (27.8)49 (25.5)40 (25.8)10.8CXD218 (30.9)15 (8.3)15 (10.00)14 (7.95)42 (23.8)0.0Stroker12.70 (80.17.0)15 (8.3)15 (0.08.1)14 (7.95)42 (23.8)0.0Lutantomation12.70 (80.17.0)15 (8.3)15.00 (80.17.0)14 (7.95)11.95 (7.3.1.8.0)1.00Nuturophi, Ma43.95 (50.00, 83.9)38.90 (7.00.2084.20 (7.25.8.07.8)48.07 (6.5.8.08.1)0.05.5.8.1.8.00.00Plater, Ma23.05 (10.1.30.0)29.00 (14.0.7.25.00.7)10.90 (14.0.0.7.00)16.75 (10.1.0.0.25.1.5.0)0.000.00Nuturophi, Ma03.90 (14.0.7.27.01)20.90 (14.0.7.25.00.7)10.90 (14.0.0.7.01)16.75 (12.0.0.25.1.5.0)0.00Plater, Ma93.05 (13.9.1.0)20.90 (14.0.7.25.00.7)10.90 (14.0.0.0.10)16.75 (12.0.0.25.1.5.0)0.00Nuturophi, Ma19.55 (12.9.1.3.0)20.91 (13.9.1.3.0)10.90 (13.0.1.0.0)10.90 (13.0.1.0.0)10.90 (13.0.1.0.0)10.90Plater, Ma12.01 (20.1.2.3)13.01 (27.0.0.1.0.0)13.00 (13.0.1.0.0)13.00 (13.0.1.0.0)13.00 (13.0.1.0.0)13.00 (13.0.1.0.0)13.00 (13.0.1.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)13.00 (13.0.0.0.0)<	Diabetes	266 (37.80)	72 (40.22)	61 (35.26)	77 (43.75)	56 (31.82)	0.100			
CKD218 (309)77 (329)57 (2.95)42 (2.3.80)42 (2.3.80)0.043Stroke15 (8.30)18 (10.40)14.705)10.5.68)0.10.5.800.10Laboatory12.70 (8.60, 17.60)11.60 (8.40, 15.70)13.50 (8.95, 17.60)13.95 (9.83, 19.90)11.95 (7.3.3, 18.05)0.004Neutrophi, %83.95 (7.60, 8.87)84.00 (7.05, 8.87.0)84.30 (7.65, 8.87.0)84.30 (7.65, 8.87.0)84.30 (6.8.5, 8.8.2.)8.300 (8.35, 8.8.2.)0.004Yamboyte, %83.05 (1.0.13.00)9.10 (5.10, 13.40)7.90 (5.3.0, 13.50)2.150 (14.00, 3.10.00)0.157 (0.10, 20.52.5.)0.001NER9.94 (5.8, 16.64)9.01 (6.09, 7.160)11.47 (5.6, 16.64)11.47 (4.19.19)8.52 (5.8.1, 4.8.4)0.035PR9.94 (5.8, 16.64)9.23 (117.0, 40.74)20.93 (12.9, 4.10, 10.10, 26.64.4)0.0140.014PR19.51 (1.9.8, 33.7)19.32 (117.0, 40.74)20.93 (12.9, 4.10, 10.10, 26.64.4)0.014Hematorit, %32.20 (7.8.0, 70.4)31.30 (27.0, 4.50)33.30 (28.8.0, 7.00)32.60 (7.8.0, 7.8.7)31.65 (7.3.3, 7.3.7)0.165 (7.3.3, 7.3.7)0.165 (7.3.3, 7.3.7)0.165 (7.3.0.8.0)0.014Patsaim, mEg/L32.00 (7.8.0, 11.90)13.00 (7.3.0, 40)42.0 (3.8.0, 40)1.900 (13.60, 14.20)0.160 (1.9.0, 10.10)0.160Patsaim, MEg/L13.00 (13.00, 11.90)13.00 (13.00, 11.90)13.00 (13.00, 11.90)13.00 (13.00, 11.90)13.00 (13.00, 11.90)13.00 (13.00, 11.90)13.00 (13.00, 11.90)13.00 (13.00, 11.90)13.00 (13.00, 11.90)13.00 (Hyperlipidemia	196 (27.84)	56 (31.28)	46 (26.59)	49 (27.84)	45 (25.57)	0.649			
Stroken15 (s30)18 (104)14 (75)10 (16.8)0.04LaboratorWBC Map120 (80.07.08.01.70)130.03 (80.17.08.01130.03 (80.19.08.01)130.03 (80.19.08.01)130.03 (80.03.08.08.01)0.001Naturopha Map83.95 (70.03.000)83.00 (70.03.00)84.00 (70.58.08.01)84.00 (70.58.08.01)83.00 (80.03.08.08.01)0.001Panden Map83.95 (70.03.000)10.01 (70.01.000)	CKD	218 (30.96)	67 (37.43)	57 (32.95)	52 (29.55)	42 (23.86)	0.043			
Laboratory parameter UNEX Second Sec	Stroke	57 (8.09)	15 (8.38)	18 (10.40)	14 (7.95)	10 (5.68)	0.450			
WBC, Kul12.70 (8.60, 17.00)11.60 (8.40, 15.70)13.50 (8.95, 17.60)13.95 (9.83, 19.90)11.95 (7.33, 18.05)0.0000Neutrophi, %83.95 (76.00, 88.97)83.90 (77.00, 89.00)84.20 (77.25, 88.75)84.70 (75.55, 89.00)83.00 (83.5, 88.25)0.011Jupphocyte, %03.00 (140.25, 274.00)20.00 (15.00, 271.00)17.00 (44.01, 10.00)19.15 (5.63, 10.00)0.015Patlet, K1/409.94 (5.84, 16.65)9.01 (6.09, 17.00)10.47 (5.67, 16.40)11.44 (7.04, 19.90)8.52 (5.82, 14.83)0.015PIR05.16 (13.89, 35.73)12.91 (13.88, 38.51)10.53 (2.110, 37.057)20.80 (2.59, 4.03.12)16.21 (10.10, 26.06)0.010Hemoglobin, g/d110.70 (2.01, 2.30)23.10 (2.74, 0.550)10.92 (2.15, 0.01, 2.10)16.21 (10.10, 20.66)0.010Hemoglobin, g/d210.70 (2.01, 2.30)13.00 (2.74, 0.550)13.00 (2.80, 4.76)14.00 (13.00, 13.01)14.00Hendoglobin, g/d213.90 (13.60, 14.20)13.90 (13.60, 14.20)13.90 (13.60, 14.20)14.00 (13.60, 14.20)1	Laboratory paramete	rs								
Neutrophil, % 83.95 (76.00, 88.97) 83.90 (77.00, 89.00) 84.20 (77.25, 88.75) 84.70 (76.55, 89.00) 83.00 (68.35, 88.25) 0.013 Lymphoyte, % 8.30 (51.01, 13.00) 9.10 (5.10, 13.40) 7.90 (5.30, 13.50) 7.20 (4.43, 11.07) 9.15 (5.63, 13.30) 0.050 Platelet, K/ul 203.00 (140.25, 274.00) 2000 (166.00, 271.00) 10.04 (5.67, 16.64) 11.48 (7.04, 19.91) 8.82 (5.82, 14.83) 0.0169 PNR 20.57 (12.91, 31.21) 23.31 (15.72, 36.94) 19.93 (11.89, 28.27) 20.93 (12.69, 7.30) 10.50 (9.13, 21.00) 0.000 Hemadocrin, % 32.20 (27.80, 37.00) 31.30 (27.40, 35.50) 33.30 (28.09, 37.60) 31.65 (27.33, 37.55) 0.103 Potassium, mEq/L 4.20 (3.70, 4.70) 4.10 (3.70, 4.60) 4.20 (3.80, 4.80) 4.20 (3.70, 4.70) 4.40 (3.80, 4.90) 0.103 Sodium, mEq/L 1.390 (136.00, 14.20) 1.390 (136.00, 14.00) 1.390 (136.00, 14.00) 1.390 (136.00, 14.00) 3.20 (27.00, 37.00) 2.60 (2.70, 3.72) 1.40 (0.70, 1.70) Albumin, g/d 3.00 (25.00, 4.01) 1.390 (136.00, 14.00) 1.390 (136.00, 14.00) 3.200 (27.00, 3.20) 2.60 (2.0, 3.00)	WBC, K/ul	12.70 (8.60, 17.60)	11.60 (8.40, 15.70)	13.50 (8.95, 17.60)	13.95 (9.83, 19.90)	11.95 (7.33, 18.05)	0.004			
Jymphoryte, %8.30 (10, 13, 00)9.10 (5.10, 13, 00)7.70 (3.0, 10, 3.0)7.70 (4.43, 11, 07)9.15 (5.3, 13, 30)9.00 (3.0)Platele, Kiul9.03 (0.0, 10, 25, 27, 40)9.00 (16.00, 27, 10)1.160 (7.0, 10, 20, 10)1.50 (10.20, 0.52, 30)1.00 (10.00, 10, 10)1.00 (10.00,	Neutrophil, %	83.95 (76.00, 88.97)	83.90 (77.00, 89.00)	84.20 (77.25, 88.75)	84.70 (76.55, 89.00)	83.00 (68.35, 88.25)	0.034			
Platelet, Kvlul203.00 (140.25, 274.00)20.00 (165.00, 271.00)192.00 (146.00, 258.00)114.8 (7.04, 19.91)167.5 (10.200, 265.2)4.003NLR9.94 (5.98, 16.65)9.01 (6.09, 17.00)19.93 (11.89, 28.27)20.08 (12.69, 27.93)17.97 (11.67, 32.49)0.003PIR10.16 (11.98.33, 337.37)22.01 (13.88, 39.51.7)16.93 (17.04, 307.54)20.93 (12.95, 44.03.12)16.82 (10.0.7, 26.64)<.0011	Lymphocyte, %	8.30 (5.10, 13.00)	9.10 (5.10, 13.40)	7.90 (5.30, 13.50)	7.20 (4.43, 11.07)	9.15 (5.63, 13.30)	0.050			
NLR9.94 (5.98, 16.65)9.01 (6.09, 17.06)10.47 (5.7, 16.64)11.48 (7.04, 19.91)8.52 (5.82, 14.83)0.003PNR20.57 (12.91, 31.21)23.31 (15.72, 36.94)19.93 (11.89, 23.72)20.08 (12.69, 27.93)17.97 (11.67, 32.49)0.001PLR105.16 (11.98, 33.73)23.21 (13.72, 36.94)19.09 (9.55, 12.70)10.60 (9.03, 12.01)10.01 (9.01, 12.01)0.101Hemadochi, M32.02 (77.80, 70.0)31.00 (20.01, 35.0)33.02 (28.80, 37.00)32.60 (27.80, 77.0)31.65 (27.33, 37.30)0.101Potassium, mEq/L42.03 (3.00, 14.00)11.90 (13.50, 14.20)13.90 (13.60, 14.10)13.90 (13.60, 14.10)14.00 (3.60, 14.10)14.00 (3.60, 14.10)Potassium, mEq/L13.00 (13.00, 14.20)11.90 (13.50, 14.20)13.90 (13.60, 14.10)12.90 (13.60, 14.10)14.00 (13.60, 14.10)14.00Potassium, mEq/L13.00 (13.00, 14.00)11.00 (13.00, 14.00)32.00 (2.01, 31.00)2.90 (2.01, 33.00)2.50 (2.01, 31.20)4.00Potassium, mEq/L13.00 (12.00, 43.02)14.00 (13.00, 14.00)33.00 (19.00, 14.00)3.00 (2.00, 48.20)11.00 (13.00, 14.00)4.00Potassium, mEq/L15.00 (10.00, 30)14.00 (13.00, 14.00)3.00 (12.00, 48.20)13.10 (19.00, 73.10)14.00 (13.00, 14.00)4.00Potassium, mEq/L11.00 (14.00, 40.00)13.00 (13.00, 14.00)13.00 (13.00, 14.00)13.00 (13.00, 14.00)4.00Potassium, mEq/L10.10 (14.00, 40.00)10.00 (10.00, 73.00)14.00 (13.00, 14.00)13.00 (13.00, 14.00)13.00 (13.00)Potassium, mEq/L<	Platelet, K/ul	203.00 (140.25, 274.00)	220.00 (165.00, 271.00)	192.00 (146.00, 258.00)	215.00 (140.00, 301.00)	167.50 (102.00, 265.25)	< 0.001			
PNR20.57 (12.91, 31.2)23.31 (15.72, 36.4)19.93 (11.89, 28.7)20.08 (12.69, 27.8)17.97 (11.67, 32.4)10.00PLR195.16 (11.98, 33.73)22.91 (13.89, 35.5)10.92 (17.04, 07.4)20.30 (20.54, 40.1)10.21 (10.10, 20.66)3.00Hemator(M)32.02 (72.03, 37.4)13.00 (74.03, 50.5)33.08 (23.60, 37.60)32.02 (72.03, 37.6)10.10Potasium, mEq/L42.03 (0.04, 0.01)41.01 (0.04, 0.01)13.00 (13.60, 14.00)32.00 (13.60, 14.00)13.00 (13.60, 14.00) <td>NLR</td> <td>9.94 (5.98, 16.65)</td> <td>9.01 (6.09, 17.06)</td> <td>10.47 (5.67, 16.64)</td> <td>11.48 (7.04, 19.91)</td> <td>8.52 (5.82, 14.83)</td> <td>0.035</td>	NLR	9.94 (5.98, 16.65)	9.01 (6.09, 17.06)	10.47 (5.67, 16.64)	11.48 (7.04, 19.91)	8.52 (5.82, 14.83)	0.035			
PLR 195.16 (119.89, 337.87) 229.16 (138.98, 395.71) 169.32 (117.04, 307.54) 209.36 (129.54, 403.12) 168.21 (101.07, 266.64) < Hemoglobin, g/dl 10.70 (9.20, 12.30) 10.30 (9.00, 11.90) 10.90 (9.55, 12.70) 10.60 (9.03, 12.40) 10.50 (9.13, 12.10) 0.130 Pensation, mEq/L 32.20 (27.80, 37.00) 31.30 (27.40, 35.50) 33.30 (28.80, 37.60) 32.60 (27.80, 37.75) 31.65 (27.33, 37.35) 0.103 Potassium, mEq/L 42.00 (37.04, 700) 4.10 (37.04, 46.00) 42.00 (38.00, 11.80) 10.400 13.00 13.00 (136.00, 14.20) 13.00 (136.00, 14.20) 14.00 (136.00, 14.20) 44.00 (38.00, 14.00) 0.103 Solum, mEq/L 2.10 (1.40, 3.60) 1.10 (0.90, 1.30) 1.80 (1.55, 2.10) 2.60 (2.13, 3.28) 5.15 (4.00, 7.47) <.0011	PNR	20.57 (12.91, 31.21)	23.31 (15.72, 36.94)	19.93 (11.89, 28.27)	20.08 (12.69, 27.93)	17.97 (11.67, 32.49)	0.004			
Hemoglobin g/dl10.70 (9.20, 12.30)10.30 (9.00, 11.90)10.90 (9.55, 12.70)10.60 (9.31, 24.00)10.50 (9.13, 12.10)0.103Hematocit, %32.20 (27.80, 37.00)31.30 (27.40, 35.50)33.30 (28.80, 37.60)32.60 (27.80, 37.70)31.65 (27.33, 37.35)0.103Potasium, mEq/L4.20 (3.70, 4.70)4.10 (3.70, 4.60)4.20 (3.80, 4.80)42.00 (3.70, 4.70)4.20 (3.80, 4.80)0.103Sodium, mEq/L1.20 (1.01, 3.60)1.10 (0.90, 1.30)1.80 (1.55, 2.10)2.60 (2.13, 32.80)5.15 (4.00, 7.47)<0.001	PLR	195.16 (119.89, 337.87)	229.16 (138.98, 395.17)	169.32 (117.04, 307.54)	209.36 (129.54, 403.12)	168.21 (101.07, 266.64)	< 0.001			
Hematocrit, %32.20 (27.80, 37.00)31.30 (27.40, 35.50)33.30 (28.80, 37.00)32.60 (27.80, 37.75)31.65 (27.33, 37.35)0.103Potassium, mEq/L4.20 (3.70, 4.70)4.10 (3.70, 4.60)4.20 (3.80, 4.80)4.20 (3.70, 4.70)4.20 (3.80, 4.90)0.400Sodium, mEq/L13.900 (136.00, 142.0)13.900 (136.00, 142.0)13.900 (136.00, 142.0)14.00 (3.60, 0.74.00)0.101Lactate, mmol/L2.10 (1.04, 3.60)1.10 (0.90, 1.30)1.80 (1.50, 1.00)2.60 (2.13, 3.20)5.15 (4.00, 7.47)<0.012	Hemoglobin, g/dl	10.70 (9.20, 12.30)	10.30 (9.00, 11.90)	10.90 (9.55, 12.70)	10.60 (9.03, 12.40)	10.50 (9.13, 12.10)	0.130			
Petasiam,mEq/L4.20 (370,47.0)4.10 (370,46.0)4.20 (380,48.0)4.20 (370,47.0)4.20 (380,49.0)0.018Sodum,mEq/L1300 (136.00,142.0)1300 (135.00,142.0)1300 (136.00,142.0)1300 (136.00,142.0)1400 (136.00,142.0)	Hematocrit, %	32.20 (27.80, 37.00)	31.30 (27.40, 35.50)	33.30 (28.80, 37.60)	32.60 (27.80, 37.75)	31.65 (27.33, 37.35)	0.103			
Sodium, mEq/L139.00 (136.00, 142.00)139.00 (135.00, 142.00)139.00 (136.00, 142.07)140.00 (136.00, 143.00)0.154Lactate, mmol/L2.10 (1.40, 3.60)1.10 (0.90, 1.30)1.80 (1.55, 2.10)2.60 (2.13, 3.28)5.15 (4.00, 7.47)<.0001	Potassium, mEq/L	4.20 (3.70, 4.70)	4.10 (3.70, 4.60)	4.20 (3.80, 4.80)	4.20 (3.70, 4.70)	4.20 (3.80, 4.90)	0.408			
Lactate, mmol/L2.10 (1.40, 3.60)1.10 (0.90, 1.30)1.80 (1.55, 2.10)2.60 (2.13, 3.28)5.15 (4.00, 7.47)<.0001Albumin, g/dl3.00 (2.50, 3.40)3.20 (2.90, 3.60)3.10 (2.70, 3.40)2.90 (2.40, 3.30)2.60 (2.20, 3.00)<.0101	Sodium, mEq/L	139.00 (136.00, 142.00)	139.00 (135.00, 142.00)	139.00 (136.00, 141.00)	139.00 (136.00, 142.75)	140.00 (136.00, 143.00)	0.154			
Albunin, g/dl3.00 (2.50, 3.40)3.20 (2.90, 3.60)3.10 (2.70, 3.40)2.90 (2.40, 3.30)2.60 (2.20, 3.00)<.0101Sr, mg/dl1.50 (1.00, 2.30)1.40 (0.90, 2.60)1.50 (1.10, 2.10)1.40 (1.00, 2.20)1.70 (1.10, 2.60)0.12BUN, mg/dl31.00 (20.00, 50.75)31.00 (19.00, 54.00)33.00 (19.50, 51.00)30.00 (20.00, 48.25)32.00 (20.00, 49.75)0.75cTNT, ng/ml0.11 (0.40, 0.30)0.09 (0.40, 0.34)0.10 (0.40, 0.39)0.12 (0.40, 0.32)0.12 (0.05, 0.48)0.81CK-MB, ng/ml9.00 (50.00, 2.200)7.00 (40.01, 51.00)42.00 (21.50, 9.02)46.00 (27.25, 91.90)83.05 (40.00, 29.00) <cd><cd><cd><cd><cd><cd><cd><cd><cd><c< td=""><td>Lactate, mmol/L</td><td>2.10 (1.40, 3.60)</td><td>1.10 (0.90, 1.30)</td><td>1.80 (1.55, 2.10)</td><td>2.60 (2.13, 3.28)</td><td>5.15 (4.00, 7.47)</td><td>< 0.001</td></c<></cd></cd></cd></cd></cd></cd></cd></cd></cd>	Lactate, mmol/L	2.10 (1.40, 3.60)	1.10 (0.90, 1.30)	1.80 (1.55, 2.10)	2.60 (2.13, 3.28)	5.15 (4.00, 7.47)	< 0.001			
Scr, mg/d 1.50 (1.00, 2.30) 1.40 (0.00, 2.60) 1.50 (1.10, 2.10) 1.40 (1.00, 2.20) 1.70 (1.10, 2.60) 0.12 BUN, mg/dl 31.00 (20.00, 50.75) 31.00 (19.00, 54.00) 33.00 (19.00, 51.00) 30.00 (20.00, 48.25) 32.00 (20.00, 49.75) 0.795 cTNT, ng/ml 0.11 (0.04, 0.36) 0.09 (0.04, 0.34) 0.10 (0.04, 0.39) 0.12 (0.04, 0.32) 0.12 (0.05, 0.48) 0.861 CK-MB, ng/ml 9.00 (5.00, 22.00) 7.00 (4.00, 15.00) 8.20 (4.30, 22.00) 9.00 (5.00, 7.50) 13.30 (7.00, 35.00) <c.001< td=""> ALT, TU/L 47.00 (24.00, 106.00) 31.00 (19.00, 7.035) 42.00 (21.50, 90.23) 46.00 (27.25, 91.98) 83.05 (40.00, 29.02) <c.001< td=""> AST, TU/L 0.07 (0.50, 110.0) 50.00 (27.00, 104.00) 65.00 (38.50, 119.00) 64.53 (37.25, 137.94) 156.50 (59.75, 47.450) <c.001< td=""> AST, TU/L 0.07 (0.50, 10.00) 6.00 (50.00, 80.00) 7.00 (50.00, 80.01) 0.09 (0.00, 80.10) 10.00 (7.00, 13.00) <c.001< td=""> SIR score 7.00 (5.00, 10.00) 6.00 (50.00, 80.00) 3.00 (3.00, 4.00) 3.00 (3.00, 4.00) 3.00 (3.00, 4.00) <c.001< td=""></c.001<></c.001<></c.001<></c.001<></c.001<>	Albumin, g/dl	3.00 (2.50, 3.40)	3.20 (2.90, 3.60)	3.10 (2.70, 3.40)	2.90 (2.40, 3.30)	2.60 (2.20, 3.00)	< 0.001			
BUN, mg/dl31.00 (20.00, 50.70)31.00 (19.00, 54.00)33.00 (19.00, 51.00)30.00 (20.00, 48.20)32.00 (20.00, 49.75)0.70cTNT, ng/ml0.11 (0.04, 0.36)0.09 (0.04, 0.34)0.10 (0.04, 0.39)0.12 (0.04, 0.32)0.12 (0.05, 0.48)0.80CK-MB, ng/ml9.00 (5.00, 22.00)7.00 (4.00, 15.00)8.20 (4.30, 22.00)9.00 (5.00, 17.00)13.30 (7.00, 35.00)<0.001	Scr, mg/dl	1.50 (1.00, 2.30)	1.40 (0.90, 2.60)	1.50 (1.10, 2.10)	1.40 (1.00, 2.20)	1.70 (1.10, 2.60)	0.127			
cTNT, ng/ml0.11 (0.04, 0.36)0.09 (0.04, 0.34)0.10 (0.04, 0.39)0.12 (0.04, 0.32)0.12 (0.05, 0.48)0.861CK-MB, ng/ml9.00 (5.00, 22.00)7.00 (4.00, 15.00)8.20 (4.30, 22.00)9.00 (5.00, 17.00)13.30 (7.00, 35.00)<0.001	BUN, mg/dl	31.00 (20.00, 50.75)	31.00 (19.00, 54.00)	33.00 (19.50, 51.00)	30.00 (20.00, 48.25)	32.00 (20.00, 49.75)	0.795			
CK-MB, ng/ml 9.00 (5.00, 22.00) 7.00 (4.00, 15.00) 8.20 (4.30, 22.00) 9.00 (5.00, 17.00) 13.30 (7.00, 35.00) <0.001 ALT, TU/L 47.00 (24.00, 106.00) 31.00 (19.00, 70.35) 42.00 (21.50, 90.23) 46.00 (27.25, 91.98) 83.05 (40.00, 290.25) <0.001	cTNT, ng/ml	0.11 (0.04, 0.36)	0.09 (0.04, 0.34)	0.10 (0.04, 0.39)	0.12 (0.04, 0.32)	0.12 (0.05, 0.48)	0.861			
ALT, TU/L 47.00 (24.00, 106.00) 31.00 (19.00, 70.35) 42.00 (21.50, 90.23) 46.00 (27.25, 91.98) 83.05 (40.00, 290.25) <0.001 AST, TU/L 70.28 (37.00, 174.75) 52.00 (27.00, 104.00) 65.00 (38.50, 119.00) 64.53 (37.25, 137.94) 156.50 (59.75, 474.50) <0.001	CK-MB, ng/ml	9.00 (5.00, 22.00)	7.00 (4.00, 15.00)	8.20 (4.30, 22.00)	9.00 (5.00, 17.00)	13.30 (7.00, 35.00)	< 0.001			
AST, TU/L 70.28 (37.00, 174.75) 52.00 (27.00, 104.00) 65.00 (38.50, 119.00) 64.53 (37.25, 137.94) 156.50 (59.75, 474.50) <0.001 LAR 0.07 (0.05, 0.12) 0.03 (0.03, 0.04) 0.06 (0.05, 0.07) 0.09 (0.08, 0.12) 0.19 (0.15, 0.28) <0.001	ALT, IU/L	47.00 (24.00, 106.00)	31.00 (19.00, 70.35)	42.00 (21.50, 90.23)	46.00 (27.25, 91.98)	83.05 (40.00, 290.25)	< 0.001			
LAR 0.07 (0.05, 0.12) 0.03 (0.03, 0.04) 0.06 (0.05, 0.07) 0.09 (0.08, 0.12) 0.19 (0.15, 0.28) <0.001 Scoring systems score 7.00 (5.00, 10.00) 6.00 (5.00, 8.00) 7.00 (5.00, 9.50) 7.00 (5.00, 10.00) 10.00 (7.00, 13.00) <0.001 SIRS score 3.00 (3.00, 4.00) 3.00 (3.00, 4.00) 3.00 (3.00, 4.00) 3.00 (3.00, 4.00) 3.00 (3.00, 4.00) 4.00 (3.00, 4.00) <0.001 gSOFA score 2.00 (2.00, 3.00) 2.00 (2.00, 3.00) 2.00 (2.00, 2.75) 2.00 (2.00, 3.00) 0.355 APSIII 64.00 (49.00, 82.00) 53.00 (40.00, 73.00) 66.00 (45.07, 74.00) 65.55 (44.00, 66.00) <0.001 SAPS II 49.00 (39.00, 60.00) 49.00 (39.00, 60.00) 49.00 (39.00, 60.00) 55.50 (44.00, 66.00) <0.001 Vasopressin use, n (%) 283 (40.19) 49 (27.37) 63 (36.42) 72 (40.91) 99 (56.25) <0.001 Ventilator use, n (%) 505 (71.73) 125 (69.83) 110 (63.58) 122 (69.32) 148 (84.09) <0.001 RT, n (%) 131 (18.61) 33 (18.44) 24 (13.87) 27 (15.34) </td <td>AST, IU/L</td> <td>70.28 (37.00, 174.75)</td> <td>52.00 (27.00, 104.00)</td> <td>65.00 (38.50, 119.00)</td> <td>64.53 (37.25, 137.94)</td> <td>156.50 (59.75, 474.50)</td> <td>< 0.001</td>	AST, IU/L	70.28 (37.00, 174.75)	52.00 (27.00, 104.00)	65.00 (38.50, 119.00)	64.53 (37.25, 137.94)	156.50 (59.75, 474.50)	< 0.001			
Scoring systems SOFA score 7.00 (5.00, 10.00) 6.00 (5.00, 8.00) 7.00 (5.00, 9.50) 7.00 (5.00, 10.00) 10.00 (7.00, 13.00) <0.001	LAR	0.07 (0.05, 0.12)	0.03 (0.03, 0.04)	0.06 (0.05, 0.07)	0.09 (0.08, 0.12)	0.19 (0.15, 0.28)	< 0.001			
SOFA score 7.00 (5.00, 10.00) 6.00 (5.00, 8.00) 7.00 (5.00, 9.50) 7.00 (5.00, 10.00) 10.00 (7.00, 13.00) <0.001 SIRS score 3.00 (3.00, 4.00) 3.00 (3.00, 4.00) 3.00 (3.00, 4.00) 3.50 (3.00, 4.00) 4.00 (3.00, 4.00) <0.001	Scoring systems									
SIRS score 3.00 (3.00, 4.00) 3.00 (3.00, 4.00) 3.00 (3.00, 4.00) 3.50 (3.00, 4.00) 4.00 (3.00, 4.00) <.001 qSOFA score 2.00 (2.00, 3.00) 2.00 (2.00, 3.00) 2.00 (2.00, 3.00) 2.00 (2.00, 2.75) 2.00 (2.00, 3.00) 0.355 APSIII 64.00 (49.00, 82.00) 53.00 (40.00, 73.00) 66.00 (46.00, 74.50) 66.00 (52.25, 81.00) 78 (62.25, 98.00) <0.001	SOFA score	7.00 (5.00, 10.00)	6.00 (5.00, 8.00)	7.00 (5.00, 9.50)	7.00 (5.00, 10.00)	10.00 (7.00, 13.00)	< 0.001			
qSOFA score 2.00 (2.00, 3.00) 2.00 (2.00, 3.00) 2.00 (2.00, 3.00) 2.00 (2.00, 2.75) 2.00 (2.00, 3.00) 0.355 APSIII 64.00 (49.00, 82.00) 53.00 (40.00, 73.00) 66.00 (46.00, 74.50) 66.00 (52.25, 81.00) 78 (62.25, 98.00) <0.001	SIRS score	3.00 (3.00, 4.00)	3.00 (3.00, 4.00)	3.00 (3.00, 4.00)	3.50 (3.00, 4.00)	4.00 (3.00, 4.00)	< 0.001			
APSIII 64.00 (49.00, 82.00) 53.00 (40.00, 73.00) 66.00 (46.00, 74.50) 66.00 (52.25, 81.00) 78 (62.25, 98.00) <0.001 SAPS II 49.00 (39.00, 60.00) 45.00 (37.00, 53.00) 47.00 (37.00, 58.00) 49.00 (39.00, 60.00) 55.50 (44.00, 66.00) <0.001	qSOFA score	2.00 (2.00, 3.00)	2.00 (2.00, 3.00)	2.00 (2.00, 3.00)	2.00 (2.00, 2.75)	2.00 (2.00, 3.00)	0.355			
SAPS II 49.00 (39.00, 60.00) 45.00 (37.00, 53.00) 47.00 (37.00, 58.00) 49.00 (39.00, 60.00) 55.50 (44.00, 66.00) <0.001 Clinical treatment Vasopressin use, n (%) 283 (40.19) 49 (27.37) 63 (36.42) 72 (40.91) 99 (56.25) <0.001	APSIII	64.00 (49.00, 82.00)	53.00 (40.00, 73.00)	60.00 (46.00, 74.50)	66.00 (52.25, 81.00)	78 (62.25, 98.00)	< 0.001			
Clinical treatment Vasopressin use, n (%) 283 (40.19) 49 (27.37) 63 (36.42) 72 (40.91) 99 (56.25) <0.001 Ventilator use, n (%) 505 (71.73) 125 (69.83) 110 (63.58) 122 (69.32) 148 (84.09) <0.001	SAPS II	49.00 (39.00, 60.00)	45.00 (37.00, 53.00)	47.00 (37.00, 58.00)	49.00 (39.00, 60.00)	55.50 (44.00, 66.00)	< 0.001			
Vasopressin use, n (%) 283 (40.19) 49 (27.37) 63 (36.42) 72 (40.91) 99 (56.25) <0.001 Ventilator use, n (%) 505 (71.73) 125 (69.83) 110 (63.58) 122 (69.32) 148 (84.09) <0.001	Clinical treatment									
Ventilator use, n (%) 505 (71.73) 125 (69.83) 110 (63.58) 122 (69.32) 148 (84.09) <0.001 RRT, n (%) 131 (18.61) 33 (18.44) 24 (13.87) 27 (15.34) 47 (26.70) 0.010	Vasopressin use, n (%)	283 (40.19)	49 (27.37)	63 (36.42)	72 (40.91)	99 (56.25)	< 0.001			
RRT, n (%) 131 (18.61) 33 (18.44) 24 (13.87) 27 (15.34) 47 (26.70) 0.010	Ventilator use, n (%)	505 (71.73)	125 (69.83)	110 (63.58)	122 (69.32)	148 (84.09)	< 0.001			
	RRT, n (%)	131 (18.61)	33 (18.44)	24 (13.87)	27 (15.34)	47 (26.70)	0.010			

TABLE 1 Baseline characteristics of participants according to the LAR quartiles.

LAR, lactate to albumin ratio; CAD, coronary artery disease; CKD, chronic kidney disease; WBC, white blood cell; NLR, neutrophil/lymphocyte ratio; PNR, platelet/neutrophil ratio; PLR, platelet/lymphocyte ratio; SCr, serum creatinine; BUN, blood urea nitrogen; cTNT, cardiac troponin T; CK-MB, creatine kinase MB isoenzyme; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SOFA, Sequential Organ Failure Assessment; SIRS, Systemic inflammatory response syndrome; qSOFA, quick Sequential Organ Failure Assessment; APSIII, Acute physiology score III; SAPSII Simplifed acute physiological score II; RRT, renal replacement therapy.

TABLE 2 The outcome events of participants according to the LAR quartiles.

Events	Overall (<i>n</i> = 704)	Q1 (<i>n</i> = 179)	Q2 (<i>n</i> = 173)	Q3 (<i>n</i> = 176)	Q4 (<i>n</i> = 176)	P-value
LOS ICU, days	5.63 (2.76, 12.21)	4.44 (2.48, 10.21)	5.74 (2.96, 11.36)	4.90 (2.63, 12.99)	6.64 (2.67, 14.15)	0.348
LOS Hospital, days	11.90 (6.60, 21.68)	10.59 (6.19, 19.15)	11.82 (7.68, 20.62)	13.55 (6.08, 21.38)	12.86 (5.22, 26.14)	0.488
ICU mortality, n (%)	161 (22.87)	24 (13.41)	31 (17.92)	39 (22.16)	67 (38.07)	< 0.001
Hospital mortality, n (%)	211 (29.97)	35 (19.55)	44 (25.43)	55 (31.25)	77 (43.75)	< 0.001

LOS, length of stay; ICU, intensive care unit.



Kaplan-meier survival analysis curves for all-cause mortality. (A) Survival probability of all-cause mortality in hospital. (B) Survival probability of all-cause mortality in ICU. ICU, intensive care unit.



FIGURE 3

Generalized additive model for association between the LAR and in-hospital mortality. (A) Generalized additive model for hospital mortality. (B) Generalized additive model for ICU mortality. HR, hazard ratio; ICU, intensive care unit; LAR, lactate to albumin ratio.



mortality.
for all-cause
(HR)
ratios
hazard
proportional
Cox
М
TABLE

Categories	Model 1 HR	<i>P</i> -value	P for trend	Model 2 HR	<i>P</i> -value	P for trend	Model 3 HR	<i>P</i> -value	P for trend	Model 4 HR	<i>P</i> -value	P for trend
Hospital mortality												
Continuous variable	1.34 (1.22–1.47)	< 0.001		1.39 (1.27–1.54)	< 0.001		1.37 (1.24–1.53)	< 0.001		1.39 (1.24–1.56)	< 0.001	
Quartile			0.002			< 0.001			0.013			0.020
Q1 $(n = 179)$	Ref.			Ref.			Ref.			Ref.		
Q2 $(n = 173)$	1.17 (0.75–1.83)	0.487		1.17 (0.75-1.82)	0.499		1.19 (0.76–1.88)	0.447		1.01 (0.64–1.61)	0.967	
Q3 $(n = 176)$	1.53 (1.00-2.34)	0.049		1.47 (0.96–2.26)	0.073		1.44 (0.94-2.22)	0.097		1.33 (0.85-2.08)	0.210	
Q4 $(n = 176)$	2.00 (1.34-3.00)	< 0.001		2.18 (1.46-3.27)	< 0.001		1.89 (1.25–2.87)	0.003		1.79 (1.16–2.77)	0.009	
ICU mortality												
Continuous variable	1.37 (1.24–1.52)	< 0.001		1.42 (1.28-1.57)	< 0.001		1.44 (1.28–1.61)	< 0.001		1.46 (1.29–1.65)	< 0.001	
Quartile			0.002			< 0.001			0.006			0.014
Q1 $(n = 179)$	Ref.			Ref.			Ref.			Ref.		
Q2 $(n = 173)$	1.18 (0.69–2.02)	0.538		1.19 (0.70-2.04)	0.513		1.17 (0.68-2.02)	0.565		1.01 (0.58-1.76)	0.973	
Q3 $(n = 176)$	1.49 (0.89–2.47)	0.126		1.45 (0.87-2.42)	0.157		1.40 (0.84–2.34)	0.201		1.31 (0.77–2.24)	0.324	
Q4 $(n = 176)$	2.21 (1.38-3.53)	< 0.001		2.31 (1.44-3.71)	<0.001		2.13 (1.31-3.46)	0.002		1.99 (1.19–3.33)	0.009	
HR, hazard ratio; Cl, cc	unfidence interval; Re	ef., reference										

Model 1: unadjusted Model 2: adjusted for age, gender, and weight. Model 3: adjusted for age, gender, weight, CAD, heart failure, atrial fibrillation, hypertension, diabetes, hyperlipidaemia, CKD, stroke, vasopressin use, ventilator use, and RRT Model 4: adjusted for age, gender, weight, CAD, heart failure, atrial fibrillation, hypertension, diabetes, hyperlipidaemia, CKD, stroke, vasopressin use, ventilator use, and RRT Model 4: adjusted for age, gender, weight, CAD, heart failure, atrial fibrillation, hypertension, diabetes, hyperlipidaemia, CKD, stroke, vasopressin use, ventilator use, RRT, WBC, neutrophil percentage, lymphocyte percentage, platelets, neutrophil/lymphocyte ratio (NLR), platelet/neutrophil ratio (PNR), platelet/lymphocyte ratio (PLR), hemoglobin, potassium, sodium, Scr, BUN, CK-MB, ALT, AST, and SIRS score



FIGURE 5

Hazard ratios (95% Cls) for hospital mortality and ICU mortality according to the LAR quartiles after adjusting for model 4. Error bars indicate 95% Cls. The first quartile is the reference. (A) Hazard ratios (95% Cls) for hospital mortality. (B) Hazard ratios (95% Cls) for ICU mortality. CI, confidence interval; LAR, lactate to albumin ratio.

Subgroup	No. of patients	Event n(%)		HR (95%CI)	P value	P for interaction
All patients	704	211 (30.0)	-	1.34 (1.22-1.47)	<0.001	
Age						0.025
<65	285	70 (24.6)	⊢ ∎	1.43 (1.27-1.62)	<0.001	
≥65	419	141 (33.7)	⊢	1.29 (1.11-1.51)	<0.001	
Gender						0.604
Female	288	85 (29.5)	⊢ ∎−−1	1.27 (1.07-1.52)	0.008	
Male	416	126 (30.3)	⊢ ∎−-1	1.35 (1.21-1.52)	<0.001	
CAD						0.580
No	481	159 (33.1)	⊢ ∎(1.34 (1.21-1.49)	<0.001	
Yes	223	52 (23.3)	k <u>−−−−−</u> 4	1.25 (0.98-1.58)	0.066	
Heart failure						0.266
No	398	134 (33.7)	⊢ ∎1	1.37 (1.23-1.52)	<0.001	
Yes	306	77 (25.2)	F =	1.17 (0.95-1.44)	0.148	
Atrial fibrillation						0.136
No	442	132 (29.9)	⊢ ∎1	1.40 (1.25-1.56)	<0.001	
Yes	262	79 (30.2)	k <u>−−</u> ∎−−−−4	1.18 (0.98-1.42)	0.074	
Hypertension						0.343
No	398	121 (30.4)	⊢ ∎	1.27 (1.11-1.47)	<0.001	
Yes	306	90 (29.4)	⊢ ∎1	1.42 (1.24-1.61)	<0.001	
Diabetes						0.368
No	438	142 (32.4)	⊢ ∎→1	1.36 (1.22-1.51)	<0.001	
Yes	266	69 (25.9)	⊢_ ∎(1.24 (0.99-1.55)	0.060	
Hyperlipidemia						0.318
No	508	158 (31.1)	⊢ ∎1	1.31 (1.18-1.46)	<0.001	
Yes	196	53 (27.0)	⊢	I 1.49 (1.18-1.88)	<0.001	
СКD						0.181
No	486	160 (32.9)	⊢ ∎1	1.38 (1.24-1.53)	<0.001	
Yes	218	51 (23.4)	F =	1.16 (0.91-1.47)	0.227	
Stroke						0.200
No	647	194 (30.0)	⊢ ∎1	1.36 (1.23-1.49)	<0.001	
Yes	57	17 (29.8)	F	0.78 (0.37-1.66)	0.522	
Vasopressin use						0.396
No	421	92 (21.9)	► -	1.40 (1.18-1.66)	<0.001	
Yes	283	119 (42.0)	► -	1.28 (1.13-1.45)	<0.001	
Ventilator use						0.050
No	199	28 (14.1)	⊢ ⊢ ■	— 1 .58 (1.26–1.98)	<0.001	
Yes	505	183 (36.2)	⊢ ∎→1	1.27 (1.15-1.42)	<0.001	
RRT						0.469
No	573	163 (28.4)	► ■ → 1	1.38 (1.24-1.54)	<0.001	
Yes	131	48 (36.6)	⊢	1.27 (1.02-1.57)	0.030	

FIGURE 6

Forest plot of the relationship between hospital mortality and LAR for subgroup analysis. CAD, coronary artery disease; CKD, chronic kidney disease; RRT, renal replacement therapy.



with ventilator use [HR (95% CI) 1.27 (1.15–1.42)], those without RRT [HR (95% CI) 1.38 (1.24–1.54)], and those with RRT [HR (95% CI) 1.27 (1.02–1.57)], the LAR was significantly associated with higher risk of hospital mortality (P<0.05). However, the forest plot showed no significant interaction of LAR by subgroup except for age (P for interaction: 0.050–0.604). This indicates that LAR is an independent prognostic factor. Stratified analyses of LAR and ICU mortality showed similar results (**Supplementary Figure S1**).

3.4. ROC curve analysis and prediction of mortality

Firstly, we plotted ROC curves for 3 indicators, LAR, lactate and albumin, to predict in-hospital all-cause mortality in patients with SMI. The result showed that the area under the curve (AUC) of LAR [0.63 (95% CI: 0.58–0.67)] was superior to that of lactate [0.62 (95% CI: 0.57–0.67)] and albumin [0.55 (95% CI: 0.50–0.59)] (Figure 7A). Similar results were found in the ICU mortality (Figure 7B). Thus, LAR had a higher predictive value than lactate and albumin.

Secondly, we also used ROC curves to assess the predictive power of the LAR, SOFA and SAPS II score for in-hospital allcause mortality in patients with SMI. The AUC of SOFA is 0.62, while the AUC of LAR plus SAPS II is 0.64 for hospital mortality (**Supplementary Figure S2A**). Furthermore, the AUC of SAPS II plus LAR for ICU mortality rate were 0.66 and 0.67, respectively (**Supplementary Figure S2B**). When LAR was added to SOFA, IDI showed significant improvements of 2.03% (95% CI: 0.77%–3.30%, P = 0.002) and 2.63% (95% CI: 0.96%–4.29%, P = 0.002) in both the hospital mortality and ICU mortality. NRI also exhibited statistical significance for both hospital mortality (31.10%, 95% CI: 15.25–46.95%, P < 0.001) and ICU mortality (31.61%, 95% CI: 14.23–48.99%, P < 0.001) (Table 4).

The AUC for SAPS II was 0.68, compared with 0.70 for LAR plus SAPS II for hospital mortality (P = 0.049) (Supplementary Figure S2C). In addition, for ICU mortality, the AUC for SAPS II and the LAR plus SAPS II were 0.68 and 0.71, respectively (P = 0.030) (Supplementary Figure S2D). Similarly, when LAR was added to SAPS II, the IDI and NRI also show significant improvement (Table 4).

4. Discussion

SMI is a reversible myocardial injury that requires early assessment to accurately stratify the disease and apply appropriate therapeutic measures. Our research suggests that the LAR can serve as a predictive indicator of mortality in SMI patients.

Serum lactate is a marker of tissue hypoperfusion and is commonly used to evaluate the severity of patients in the ICU (24). Recent study has demonstrated a correlation between lactate levels and adverse outcomes in critically ill patients (25). Furthermore, research has indicated an association between elevated lactate levels and a poor prognosis in sepsis patients (26). Our study also observed elevated serum lactate levels in SMI patients with a poor prognosis. Therefore, elevated lactate levels can be used as an indicator of a poor prognosis in SMI patients. However, it is important to exercise caution when interpreting lactate levels, as certain medications or conditions can also lead to their elevation (27, 28). Consequently, it would be insufficient to rely solely on lactate levels to predict the prognosis of patients with SMI.

Index	AUC (95% CI)	IDI (%) (95% CI)	<i>P</i> -value	NRI (%) (95% CI)	<i>P</i> -value
Hospital mortality					
LAR	0.63 (0.58-0.67)	-	-	-	-
SOFA	0.62 (0.57-0.67)	Ref.	Ref.	Ref.	Ref.
SAPS II	0.68 (0.64-0.73)	Ref.	Ref.	Ref.	Ref.
LAR + SOFA	0.64 (0.59-0.68)	2.03 (0.77-3.30)	0.002	31.10 (15.25-46.95)	< 0.001
LAR + SAPS II	0.70 (0.66-0.74)	2.79 (1.14-4.45)	< 0.001	19.84 (4.69-34.99)	0.010
ICU mortality					
LAR	0.65 (0.60-0.70)	-	-	-	-
SOFA	0.66 (0.61-0.71)	Ref.	Ref.	Ref.	Ref.
SAPS II	0.68 (0.63-0.73)	Ref.	Ref.	Ref.	Ref.
LAR + SOFA	0.67 (0.62-0.72)	2.63 (0.96-4.29)	0.002	31.61 (14.23-48.99)	<0.001
LAR + SAPS II	0.71 (0.66–0.75)	3.90 (1.85-5.95)	< 0.001	29.69 (12.79-46.58)	<0.001

TABLE 4 The addition of LAR improved the predictive ability of the scoring system for mortality.

AUC, area under the curve; CI, confidence interval; IDI, integrated discrimination improvement; NRI, net reclassification improvement index; LAR, lactate to albumin ratio; SOFA, Sequential Organ Failure Assessment; SAPS II, Simplifed acute physiological score II; Ref., reference.

Albumin, a multifunctional protein with roles in antioxidant defense, anti-inflammatory action, and maintenance of vascular endothelial function, has been shown to mitigate the detrimental effects of infection-driven inflammatory responses on the body and reduce the incidence of organ failure. However, in patients suffering from severe infections, albumin is markedly reduced, which is associated with adverse clinical outcomes. A plethora of clinical studies have demonstrated that low levels of albumin are linked to increased mortality risk in conditions including sepsis, septic shock, and heart failure (29, 30). Notably, inflammation can augment capillary permeability, leading to leakage of albumin out of blood vessels, resulting in a decline of serum albumin levels (31). Prolonged inflammation may exacerbate this process, ultimately culminating in more severe inflammation (8, 32). In patients with SMI, excessive activation of the immune system leads to extensive albumin consumption, which significantly contributes to poor prognosis.

However, the utility of serum albumin as a prognostic indicator may be limited by other factors such as chronic disease, malnutrition, and inflammation (17). Cakir et al. noted the albumin's prognostic value may be restricted, especially in elderly individuals who are frail (33). Moreover, Finfer et al. showed no significant improvement in mortality among patients with severe sepsis treated with albumin therapy (34). Additionally, Chen et al. indicated that the infusion of exogenous albumin may interfere with the diagnostic capabilities of serum albumin (35). Hence, the prognostic value of albumin is influenced by multiple factors, which limit its clinical utility.

The LAR is a composite indicator that considers both the nutritional and inflammatory status of critically ill patients, thereby reducing the impact of individual factors on regulatory mechanisms. This feature makes it an accurate prognostic biomarker for various diseases. Several studies have demonstrated that LAR has superior predictive value compared to lactate alone in determining outcomes in severely infected patients (19, 33, 36). In patients with severe sepsis and septic shock, elevated LAR levels are associated with the development of multiple organ dysfunction syndrome (MODS) and mortality (37, 38). Notably, Michael et al. have proposed the use of LAR as a novel predictor

for stratifying sepsis patients based on the severity of their disease (39). Additionally, LAR has shown promising results in predicting prognosis in critically ill patients with cardiovascular diseases such as heart failure, myocardial infarction, and cardiac arrest (20, 21, 40). Consequently, LAR may serve as a more effective clinical predictor for critically ill patients with SMI. Our study, based on database analysis, found that higher LAR levels were associated with a higher risk of mortality in SMI patients, both during hospitalization and ICU admission, which is consistent with previous findings. Furthermore, we observed that LAR had a better predictive value than either lactate or albumin alone in SMI patients.

To date, there are few studies on the association between LAR and critically ill patients with SMI. Zhang et al. found the diagnostic value of LAR for severe pneumonia and myocardial injury (22). However, the prognostic value of LAR was not evaluated in this study. In addition, our study is the first to establish the significance of LAR as a prognostic marker for hospital mortality and ICU mortality among SMI patients. In our study, higher level of LAR, lactate, and lower albumin levels were observed in the non-survival group of SMI patients. Moreover, we observed that both hospital and ICU mortality rates increased with elevating LAR levels. Similarly, Gharipour et al. found a positive association between LAR and future adverse events in critically ill patients (41). Additionally, another study investigating 1,381 sepsis patients demonstrated that higher LAR was associated with a greater risk of mortality (42). Using Cox proportional risk analysis and Kaplan-Meier survival analysis, we obtained comparable findings: increasing LAR levels correlated positively with an elevated risk of mortality, with the risk gradually escalating as LAR levels increased in SMI patients. Drăgoescu AN et al. showed the predictive potential of NLR for sepsis mortality (43), while Kriplani A et al. found the diagnostic value of NLR and PLR for sepsis (44). In our study, we found that increased LAR was a strong independent predictor of higher mortality in patients with SMI. This finding persisted even after making adjustments for potential confounders such as NLR, PNR, and PLR (Model 4, P < 0.001). Furthermore, both the results of the GAM and the RCS model indicated a significant

linear correlation between the LAR and all-cause mortality in SMI patients. Importantly, our study established that higher LAR levels correlated with increased hospital and ICU mortality risks. Consequently, our findings permit early identification of patients with high mortality risks, and monitoring LAR may aid in improved management of SMI patients in clinical practice. This is particularly vital for better clinical management to reduce future adverse events.

Our subgroup analysis demonstrated that LAR maintains consistent predictive value across different age and gender groups in patients. Remarkably, Guo W et al. revealed that elevated LAR levels correlated with increased risks of both short- and longterm mortality in patients with heart failure (20). Nevertheless, our study identified a higher risk of mortality in patients without underlying conditions such as CAD, heart failure, atrial fibrillation, CKD, and stroke. Interestingly, as the LAR levels increased, the incidence of these aforementioned diseases decreased, which can be attributed to reverse causality wherein patients with pre-existing conditions were treated more intensively and had their abnormal LAR values corrected more promptly. Nonetheless, our forest plots indicated no significant interaction (P for interaction >0.05) between LAR and these subgroups, suggesting that the presence or absence of these diseases did not affect the predictive power of LAR.

The findings from our study demonstrate that LAR is a superior predictor of mortality in patients suffering from SMI. The results of our ROC analysis revealed an AUC of 0.63 for LAR in the hospital and 0.65 in the ICU. These values were higher than those observed for lactate, which were 0.62 and 0.64 respectively. Moreover, these results were consistent with prior research (18). The optimal cutoff value for predicting mortality was determined to be 0.09 for LAR (positive predictive value (PPV): 41%, negative predictive value (NPV): 77%) and 0.12 for ICU settings (PPV: 38%, NPV: 83%). A study conducted by Lichtenauer et al. on 348 sepsis patients identified an optimal cutoff value of 0.15, which was slightly greater than our findings (39). However, the discrepancy could be attributed to differences in sample size, and we recommend conducting a future prospective study to determine the optimal LAR value. Importantly, when we add LAR to SOFA and SAPS II, the IDI and NRI showed significant improvement, both in hospital mortality and ICU mortality. The above results indicate that LAR may improve the ability of severity scores to predict mortality risk.

The primary strength of our study is its confirmation of the strong association between increased LAR and higher mortality rates in SMI patients. Additionally, LAR is a simple and easily obtainable indicator when compared to other indicators. Nonetheless, several limitations should be noted. Firstly, the study was a single-center retrospective study, and therefore, causality cannot be established. Secondly, due to the large number of missing variables in the database, unadjusted confounders may have affected our results despite multivariate adjustment and subgroup analysis. Finally, our study only examined the relationship between LAR at admission and prognosis and did not assess the impact of changes in LAR on prognosis. Therefore, further studies are necessary to determine if dynamic changes in LAR can also predict mortality.

5. Conclusions

According to our research findings, there exists a positive correlation between LAR and the mortality rate of patients in ICU and hospitals who suffer from SMI. The risk of mortality in SMI patients increases proportionally with higher LAR values. Our study posits that LAR could potentially serve as a predictive indicator for mortality in SMI patients, contributing to the stratification of risk levels and prognosis prediction. It is recommended that further prospective studies be conducted to validate the predictive efficacy of LAR in SMI patients.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: https://mimic.mit.edu.

Ethics statement

The studies involving humans were approved by Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center review boards. The studies were conducted in accordance with the local legislation and institutional requirements. The Ethics Committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants' legal guardians/next of kin. The database was approved for research use by Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center review boards.

Author contributions

JZ contributed to conception, design and drafting of the manuscript. SC, SG, ZY, FO, SL, and LL contributed to data collection and manuscript drafting. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the Medical Science and Technology Research Foundation of Guangdong Province of China (Grant No. A2023151), Science and Technology Project of Foshan (Grant No. 2220001003865), Scientific Research Start Plan of Shunde Hospital, Southern Medical University (Grant No. SRSP2019004), Natural Science Foundation of Guangdong Province of China (Grant No. 2018A030313067), Science and Technology Innovation Project of Foshan, Guangdong (Grant No. FS0AA- KJ218-1301-0006; FS0AA-KJ218-1301-0010) and Key Specialist Department Training Project of Foshan, Guangdong Province of China (Grant No. Fspy 3-2015034).

Acknowledgments

All work would like to thank the Shunde Hospital, Southern Medical University, Foshan Science and Technology Bureau and Department of Science and Technology of Guangdong Province for their support.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. *Am J Respir Crit Care Med.* (2016) 193(3):259–72. doi: 10. 1164/rccm.201504-0781OC

2. Rhee C, Jones TM, Hamad Y, Pande A, Varon J, O'Brien C, et al. Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals. *JAMA Netw Open.* (2019) 2(2):e187571. doi: 10.1001/jamanetworkopen. 2018.7571

3. Bi CF, Liu J, Yang LS, Zhang JF. Research progress on the mechanism of sepsis induced myocardial injury. *J Inflamm Res.* (2022) 15:4275–90. doi: 10.2147/jir. S374117

4. Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med. (1999) 27(9):1775-80. doi: 10.1097/00003246-199909000-00012

5. Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. (2021) 18(6):424-34. doi: 10.1038/s41569-020-00492-2

6. Suetrong B, Walley KR. Lactic acidosis in sepsis: it's not all anaerobic: implications for diagnosis and management. *Chest.* (2016) 149(1):252-61. doi: 10. 1378/chest.15-1703

7. Gattinoni L, Vasques F, Camporota L, Meessen J, Romitti F, Pasticci I, et al. Understanding lactatemia in human sepsis. Potential impact for early management. *Am J Respir Crit Care Med.* (2019) 200(5):582–9. doi: 10.1164/rccm.201812-2342OC

8. Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O. Serum albumin levels and inflammation. *Int J Biol Macromol.* (2021) 184:857–62. doi: 10.1016/j. ijbiomac.2021.06.140

9. Eckart A, Struja T, Kutz A, Baumgartner A, Baumgartner T, Zurfluh S, et al. Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: a prospective study. *Am J Med.* (2020) 133(6):713–22.e7. doi: 10.1016/j.amjmed.2019.10.031

10. Kaysen GA. Biochemistry and biomarkers of inflamed patients: why look, what to assess. *Clin J Am Soc Nephrol.* (2009) 4(Suppl 1):S56–63. doi: 10.2215/cjn. 03090509

11. Chaudhry S, Haroon F, Irfan Waheed KA, Victor G, Shahzad M, Fatima B. Blood lactate levels and lactate clearance as predictors of mortality in neonatal sepsis. *J Ayub Med Coll Abbottabad.* (2022) 34(3):438–41. doi: 10.55519/jamc-03-9087

12. Vincent JL, Quintairos ESA, Couto L Jr, Taccone FS. The value of blood lactate kinetics in critically ill patients: a systematic review. *Crit Care.* (2016) 20(1):257. doi: 10.1186/s13054-016-1403-5

13. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. *Crit Care Med.* (2011) 39(2):386–91. doi: 10.1097/CCM.0b013e3181ffe217

14. Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. *Intensive Care Med.* (2011) 37(1):86–96. doi: 10.1007/s00134-010-2039-6

15. Oster JR, Perez GO. Acid-base disturbances in liver disease. J Hepatol. (1986) 2 (2):299-306. doi: 10.1016/s0168-8278(86)80089-7

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2023. 1233147/full#supplementary-material

16. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. *Drug Saf.* (2010) 33(9):727–40. doi: 10.2165/11536790-00000000-00000

17. Caironi P, Langer T, Gattinoni L. Albumin in critically ill patients: the ideal colloid? *Curr Opin Crit Care*. (2015) 21(4):302-8. doi: 10.1097/mcc.0000000000223

18. Shin J, Hwang SY, Jo IJ, Kim WY, Ryoo SM, Kang GH, et al. Prognostic value of the lactate/albumin ratio for predicting 28-day mortality in critically ILL sepsis patients. *Shock.* (2018) 50(5):545–50. doi: 10.1097/shk.00000000001128

19. Shadvar K, Nader-Djalal N, Vahed N, Sanaie S, Iranpour A, Mahmoodpoor A, et al. Comparison of lactate/albumin ratio to lactate and lactate clearance for predicting outcomes in patients with septic shock admitted to intensive care unit: an observational study. *Sci Rep.* (2022) 12(1):13047. doi: 10.1038/s41598-022-14764-z

20. Guo W, Zhao L, Zhao H, Zeng F, Peng C, Guo W, et al. The value of lactate/ albumin ratio for predicting the clinical outcomes of critically ill patients with heart failure. *Ann Transl Med.* (2021) 9(2):118. doi: 10.21037/atm-20-4519

21. Zhu JL, Liu H, Wang LL, Lu XH, Yin HY, Lyu J, et al. Association of lactate to albumin ratio and bicarbonate with short-term mortality risk in patients with acute myocardial infarction. *BMC Cardiovasc Disord*. (2022) 22(1):490. doi: 10.1186/ s12872-022-02902-4

22. Zhang L, Li Y, Lv C, Guo H, Xu T, Ma Z, et al. Predictive value of arterial blood lactate/serum albumin ratio for myocardial injury in elderly patients with severe community-acquired pneumonia. *Medicine (Baltimore)*. (2022) 101(4):e28739. doi: 10.1097/md.00000000028739

23. Johnson AE, Pollard TJ, Shen L, Lehman LW, Feng M, Ghassemi M, et al. MIMIC-III, a freely accessible critical care database. *Sci Data*. (2016) 3:160035. doi: 10.1038/sdata.2016.35

24. Ferreruela M, Raurich JM, Ayestarán I, Llompart-Pou JA. Hyperlactatemia in ICU patients: incidence, causes and associated mortality. *J Crit Care.* (2017) 42:200–5. doi: 10.1016/j.jcrc.2017.07.039

25. Gharipour A, Razavi R, Gharipour M, Modarres R, Nezafati P, Mirkheshti N. The incidence and outcome of severe hyperlactatemia in critically ill patients. *Intern Emerg Med.* (2021) 16(1):115–23. doi: 10.1007/s11739-020-02337-9

26. Yang X, Zhou Y, Liu A, Pu Z. Relationship between dynamic changes of microcirculation flow, tissue perfusion parameters, and lactate level and mortality of septic shock in ICU. *Contrast Media Mol Imaging*. (2022) 2022:1192902. doi: 10. 1155/2022/1192902

27. Smith ZR, Horng M, Rech MA. Medication-induced hyperlactatemia and lactic acidosis: a systematic review of the literature. *Pharmacotherapy*. (2019) 39(9):946–63. doi: 10.1002/phar.2316

28. Cheng CY, Kung CT, Wu KH, Chen FC, Cheng HH, Cheng FJ, et al. Liver cirrhosis affects serum lactate level measurement while assessing disease severity in patients with sepsis. *Eur J Gastroenterol Hepatol.* (2021) 33(9):1201–8. doi: 10.1097/meg.00000000001826

29. Xu JY, Chen QH, Xie JF, Pan C, Liu SQ, Huang LW, et al. Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials. *Crit Care*. (2014) 18(6):702. doi: 10.1186/s13054-014-0702-y

30. Ancion A, Allepaerts S, Oury C, Gori AS, Piérard LA, Lancellotti P. Serum albumin level and hospital mortality in acute non-ischemic heart failure. *ESC Heart Fail*. (2017) 4(2):138–45. doi: 10.1002/ehf2.12128

31. Fleck A, Raines G, Hawker F, Trotter J, Wallace PI, Ledingham IM, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. *Lancet.* (1985) 1(8432):781–4. doi: 10.1016/s0140-6736(85)91447-3

32. Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. *JPEN J Parenter Enteral Nutr.* (2019) 43(2):181–93. doi: 10.1002/jpen. 1451

33. Cakir E, Turan IO. Lactate/albumin ratio is more effective than lactate or albumin alone in predicting clinical outcomes in intensive care patients with sepsis. *Scand J Clin Lab Invest.* (2021) 81(3):225–9. doi: 10.1080/00365513.2021. 1901306

34. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med.* (2004) 350(22):2247–56. doi: 10.1056/NEJMoa040232

35. Chen Y, Yang K, Wu B, Lin W, Chen S, Xu X, et al. Association between lactate/ albumin ratio and mortality in patients with heart failure after myocardial infarction. *ESC Heart Fail.* (2023) 10(3):1928–36. doi: 10.1002/ehf2.14359

36. Sai IN, Prasad R TV. Assessing the prognostic value of crp/albumin ratio and lactate/albumin ratio in critically ill patients. *J Assoc Physicians India.* (2022) 70 (4):11–2.

37. Wang B, Chen G, Cao Y, Xue J, Li J, Wu Y. Correlation of lactate/albumin ratio level to organ failure and mortality in severe sepsis and septic shock. *J Crit Care.* (2015) 30(2):271–5. doi: 10.1016/j.jcrc.2014.10.030

38. Choi SJ, Ha EJ, Jhang WK, Park SJ. Association between the lactate/albumin ratio and mortality in pediatric septic shock patients with underlying chronic disease: retrospective pilot study. *Minerva Pediatr (Torino)*. (2021) 73(1):67–72. doi: 10.23736/s2724-5276.16.04551-5

39. Lichtenauer M, Wernly B, Ohnewein B, Franz M, Kabisch B, Muessig J, et al. The lactate/albumin ratio: a valuable tool for risk stratification in septic patients admitted to ICU. *Int J Mol Sci.* (2017) 18(9):1893. doi: 10.3390/ijms18091893

40. Kong T, Chung SP, Lee HS, Kim S, Lee J, Hwang SO, et al. The prognostic usefulness of the lactate/albumin ratio for predicting clinical outcomes in out-of-hospital cardiac arrest: a prospective, multicenter observational study (koCARC) study. *Shock.* (2020) 53(4):442–51. doi: 10.1097/shk.00000000001405

41. Gharipour A, Razavi R, Gharipour M, Mukasa D. Lactate/albumin ratio: an early prognostic marker in critically ill patients. *Am J Emerg Med.* (2020) 38(10):2088–95. doi: 10.1016/j.ajem.2020.06.067

42. Bou Chebl R, Jamali S, Sabra M, Safa R, Berbari I, Shami A, et al. Lactate/ albumin ratio as a predictor of in-hospital mortality in septic patients presenting to the emergency department. *Front Med (Lausanne).* (2020) 7:550182. doi: 10.3389/ fmed.2020.550182

43. Drăgoescu AN, Pădureanu V, Stănculescu AD, Chiuțu LC, Tomescu P, Geormăneanu C, et al. Neutrophil to lymphocyte ratio (NLR)-A useful tool for the prognosis of sepsis in the ICU. *Biomedicines.* (2021) 10(1):75. doi: 10.3390/biomedicines10010075

44. Kriplani A, Pandit S, Chawla A, de la Rosette J, Laguna P, Jayadeva Reddy S, et al. Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR) in predicting systemic inflammatory response syndrome (SIRS) and sepsis after percutaneous nephrolithotomy (PNL). *Urolithiasis.* (2022) 50(3):341–8. doi: 10.1007/s00240-022-01319-0